naproxen

(redirected from Vimovo)
Also found in: Dictionary, Thesaurus, Medical.

naproxen

and

naproxen sodium,

potent nonsteroidal anti-inflammatory drugs (NSAID) used to alleviate the minor pain of arthritis, menstruation, headaches, and the like, and to reduce fever. Along with ibuprofenibuprofen
, nonsteroidal anti-inflammatory drug (NSAID) that reduces pain, fever, and inflammation. Along with naproxen and ketoprofen, ibuprofen belongs to the propionic acid class of NSAIDs. It was first made available in 1967.
..... Click the link for more information.
 and ketoprofenketoprofen
, nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and fever-reducing effects, used to relieve the symptoms of headaches, arthritis, and painful menstruation.
..... Click the link for more information.
, they belong to the propionic acid class of NSAIDs. They have been available as prescription drugs for arthritis from 1976. Naproxen sodium was approved at a low dosage as an over-the-counter painkiller in the United States in 1994; it was first marketed under the tradename Aleve. Side effects may include gastrointestinal distress and dizziness, and renal impairment has been reported in some instances with long-term use. The drugs should not be used by those who are allergic to aspirinaspirin,
acetyl derivative of salicylic acid (see salicylate) that is used to lower fever, relieve pain, reduce inflammation, and thin the blood. Common conditions treated with aspirin include headache, muscle and joint pain, and the inflammation caused by rheumatic fever and
..... Click the link for more information.
.
References in periodicals archive ?
According to the company, VIMOVO (naproxen/esomeprazole magnesium) is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole magnesium, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.
US patent No 6,926,907 for Vimovo expires in 2023 and the drug has regulatory exclusivity until 30 April 2013.
The company said VIMOVO is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole magnesium, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.
The approval was based on clinical data that showed that patients taking Vimovo experienced significantly fewer endoscopic gastric ulcers, compared to patients receiving enteric-coated naproxen.
In the next few weeks, Pozen will transfer ownership of the investigational new drug (IND) application and the new drug application (NDA) for Vimovo to AstraZeneca.
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) disclosed on Tuesday the receipt of a Notice of Allowance for US patent application entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that covers the US approved medicine VIMOVO (naproxen/esomeprazole) delayed release tablets.
According to data from the pivotal phase III studies PN 400-301 and PN400-302, patients taking Vimovo experienced significantly fewer endoscopic gastric ulcers, compared with patients treated with enteric-coated naproxen only.
The company said the patent, consigned the US patent number 8,945,621, relates to VIMOVO (naproxen/esomeprazole magnesium) delayed release tablets in patients taking low dose aspirin.
Pharmaceutical company POZEN Inc (NASDAQ: POZN) declared on Thursday the receipt of three patents from the United States Patent and Trademark Office (USPTO), entitled 'Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs, for VIMOVO (naproxen / esomeprazole magnesium) delayed-release tablets, a US approved product.
Pharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Wednesday that it has received the US Patent and Trademark Office's (USPTO) Notice of Allowance for patent application number 14/045,156 entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" covering VIMOVO delayed release tablets.
M2 EQUITYBITES-October 23, 2014-POZEN receives three patents from USPTO covering VIMOVO delayed-release tablets